News

Horizon Therapeutics announces new data and a separate analysis will be presented at the American Academy of Neurology 2022 Annual Meeting, showing that UPLIZNA reduced disease activity associated with neuromyelitis optica spectrum disorder (NMOSD) over 3 years.

Cynthia Matossian, MD, shares her thoughts on the premium patient "experience" or "journey," emphasizing the outcomes of patient experiences.

The company’s announcement marks first clinical trial in humans of Ocugen’s modifier gene therapy platform.

Approval is based on year 1 data from the Phase III KESTREL and KITE trials investigating brolucizumab 6 mg versus aflibercept 2 mg in DME patients.

The study, by investigators from the Casey Eye Institute, Oregon Health and Science University, supported the use of at-home tests during teleophthalmology care, an important point considering the significant drop in in-person VA evaluations during the pandemic.

April is Presbyopia Awareness Month. Brieann K. Adair, OD, of NYU Langone Health, speaks with Ophthalmology Times’ Sheryl Stevenson about the importance of Presbyopia awareness, treatment options and more.

The company’s announcement marks first clinical trial in humans of Ocugen’s modifier gene therapy platform.

Bausch + Lomb and Clearside Biomedical Inc. are rolling out the new therapeutic, approved by the FDA for suprachoroidal use for the treatment of macular edema associated with uveitis.

New Zealand’s Ministry of Health has issued infringement notices to two ophthalmologists for seeing patients while unvaccinated.

In those first few months, I realized there were so many aspects of real-life, post-residency practice we had never been taught during medical school or residency.

A University of Houston study found that minorities have fewer eye exams, higher instances of disease.

If the Biologics License Application is approved by the FDA, the company could receive 12 years of marketing exclusivity for an FDA-approved alternative for the most frequently used anti-VEGF treatment in wet AMD patients in the United States.

If the BLA is approved, the company could receive 12 years of marketing exclusivity for an FDA-approved alternative for the most frequently used anti-VEGF treatment in wet AMD patients in the United States.

A separate analysis will be presented at the American Academy of Neurology 2022 Annual Meeting, showing that UPLIZNA reduced pan associated with NMOSD over 3 years.

A multifaceted evaluation that includes ultra-widefield imaging can reveal new information and influence treatment decisions.

Treatment options beginning to evolve from traditional therapies

Bausch + Lomb and Clearside Biomedical Inc. are rolling out the new therapeutic, approved by the FDA for suprachoroidal use for the treatment of macular edema associated with uveitis, a form of eye inflammation.

Beginning in the 1970s, James J. Salz, MD, was part of a group of ophthalmologists who first inserted intraocular lens implants during cataract surgery.

The American College of Medical Genetics and Genomics Foundation for Genetic and Genomic Medicine grants its Next Generation Fellowship Awards to promising early-career professionals in a range of medical genetics and genomics specialties. The awards were presented at the 2022 ACMG Clinical Genetics Meeting.

The company is planning a Phase 2 trial with an optimized formulation in wet AMD that is expected to start in fourth quarter of 2022.

Lower dose performs as effectively as a higher dose when treating ROP.

The country’s Ministry of Health has issued infringement notices to two ophthalmologist for seeing patients while unvaccinated.

Novel trial design will compare safety and effectiveness outcomes for the OMNI Surgical System and the iStent inject in lowering IOP as a standalone treatment option without concomitant cataract surgery.

The MIRA-3 Phase 3 FDA Registration trial for Nyxol met its primary endpoint with 58% of treated subjects returning to baseline pupil diameter at 90 minutes compared to 6% of placebo subjects.

The company’s iCare HOME2 self-tonometer allows patients to collect real-world IOP data at any time.

Assembling a team of experts is key for diagnosis, treatment

Suprachoroidal injections provide safe, effective drug delivery to target choroidal, retinal tissues.

Cataract surgery in children is challenging because of the likelihood of posterior capsule opacification. This can be overcome with primary posterior laser capsulotomy coupled with bag-in-the-lens technology.